Introduction to Bicycle Therapeutics plc USA

Bicycle Therapeutics plc USA stands as a pioneering biotechnology company headquartered in Cambridge, Massachusetts, with a global footprint that extends to the United Kingdom. Focused on the development of novel therapeutics based on its proprietary bicyclic peptide platform, the company has carved a distinct niche in the healthcare and pharmaceutical industry. The company’s mission is to transform the treatment paradigm for patients suffering from diseases with high unmet medical needs, particularly in oncology and rare diseases. Bicycle Therapeutics plc USA is recognized as a leader in the field of constrained peptide technologies, leveraging its unique Bicycle® platform to create molecules that combine the desirable properties of small molecules (such as tissue penetration and oral bioavailability) with the high affinity and selectivity of antibodies. This dual advantage positions the company at the forefront of precision medicine, enabling the targeting of previously undruggable targets. The company’s reputation is built on a foundation of rigorous science, strategic partnerships with major pharmaceutical firms, and a robust pipeline of proprietary candidates. Organizations ranging from large pharma to academic research centers rely on Bicycle Therapeutics’s innovative approach for drug discovery and development. The company has consistently been recognized as a top employer in the biotech sector, attracting top talent from around the world. With a strong emphasis on intellectual property, the firm holds numerous patents protecting its platform and therapeutic assets. Bicycle Therapeutics plc USA is not merely a company; it is a hub of innovation that is redefining what is possible in drug design. The firm’s scale, though modest compared to big pharma, is complemented by an agile, entrepreneurial culture that accelerates decision-making and fosters creativity. As of the latest reports, the company employs over 200 professionals across its US and UK sites, and its market capitalization reflects investor confidence in its pipeline. The company’s dedication to patient-centric science and its collaborative ethos make it a standout in the competitive landscape of modern biotechnology.

Company History and Business Evolution

Bicycle Therapeutics was founded in 2009 by a team of visionary scientists including Sir Gregory Winter, a Nobel Laureate, and Professor Christian Heinis, who pioneered the concept of bicyclic peptides. The company emerged from the Laboratory of Molecular Biology in Cambridge, UK, with the goal of translating academic discoveries into therapeutic realities. The early years were marked by proof-of-concept studies demonstrating that constrained bicyclic peptides could be engineered to bind protein targets with high affinity and specificity, overcoming the limitations of linear peptides. In 2010, the company secured its first significant venture capital funding, allowing it to expand its research capabilities and establish a US presence in Cambridge, Massachusetts. A major milestone occurred in 2014 when Bicycle Therapeutics entered into its first major collaboration with AstraZeneca, focusing on respiratory diseases, which validated the platform’s versatility. The following years saw a series of strategic partnerships and licensing agreements with pharmaceutical giants such as Novartis and Genentech, each deal bringing in nondilutive capital and underscoring the industry’s appetite for the Bicycle platform. In 2019, the company achieved a landmark event: its initial public offering on the NASDAQ stock exchange under the ticker symbol BCYC, raising over $100 million to advance its pipeline. Post-IPO, the company accelerated its lead program, BT1718, a Bicycle Toxin Conjugate targeting MT1-MMP for the treatment of solid tumors, which entered Phase I/II clinical trials. The COVID-19 pandemic posed challenges but also demonstrated resilience as the company adapted to remote work and continued trial enrollment. In 2021, Bicycle Therapeutics expanded its US headquarters in Cambridge, doubling its laboratory and office space to accommodate a growing workforce. The company also launched a strategic collaboration with Ionis Pharmaceuticals to explore bicyclic peptides for neurological diseases. By 2023, the pipeline had grown to include multiple candidates in oncology, ranging from Bicycle Toxin Conjugates to Bicycle Immuno-Oncology molecules. A key evolution was the development of a tumor-targeted interleukin-2 therapy, demonstrating the platform’s ability to modulate immune responses. Throughout its history, Bicycle Therapeutics has made selected acquisitions, including the purchase of certain assets from BicycleTx Limited to consolidate IP. The company’s evolution from a small startup to a publicly traded, late-stage clinical biotech reflects its scientific rigor, strategic foresight, and ability to forge impactful partnerships. Today, Bicycle Therapeutics continues to push boundaries, exploring bicyclic peptides for drug delivery and diagnostic applications, ensuring its place as a transformative force in modern medicine.

Bicycle Therapeutics plc USA at a Glance

• Headquarters: Cambridge, Massachusetts, USA (with R&D facility in Cambridge, UK)
• Founded: 2009
• CEO: Kevin Lee (since 2021)
• Senior Leadership: Chief Scientific Officer: Dr. Phil Chamberlain; CFO: Alistair Milnes
• Revenue: Not yet profitable; revenue from collaborations (e.g., $30M in 2022)
• Employees: ~220 (2024 estimate)
• Stock Symbol: NASDAQ: BCYC
• Market Cap: ~$1.5 billion (as of 2025)
• Core Technology: Bicycle® constrained bicyclic peptide platform
• Therapeutic Areas: Oncology, rare diseases, inflammation
• Lead Program: BT1718 (Bicycle Toxin Conjugate) in Phase II
• Collaborators: AstraZeneca, Novartis, Genentech, Ionis
• Patents: Over 100 granted patents globally
• Funding History: Raised >$400M through VC and public markets
• Awards: Fierce Biotech’s Fierce 15 (2014); Boston Business Journal’s Best Places to Work
• Regulatory Achievements: Orphan Drug Designation for BT1718 in pancreatic cancer
• Facilities: 50,000 sq ft lab & office space in Cambridge, MA
• Clinical Trials: Multiple Phase I/II studies ongoing
• Publications: 80+ peer-reviewed articles on bicyclic peptides
• Company Culture: Collaborative, innovative, patient-focused

Mission, Vision, and Core Corporate Values

Bicycle Therapeutics plc USA is driven by a clear mission: to discover and develop life-transforming medicines for patients with serious diseases, using the power of bicyclic peptide technology. The company envisions a future where its platform enables precise targeting of disease pathways that were previously considered undruggable, ultimately leading to a new class of therapies that combine the best attributes of small molecules and biologics. This vision extends beyond oncology to encompass rare genetic disorders, inflammatory conditions, and even diagnostics. The core values of the organization reflect its scientific and ethical commitments: Innovation is the bedrock, encouraging bold ideas and risk-taking in drug discovery. Integrity governs all interactions with patients, partners, and regulators, ensuring transparency and compliance. Collaboration is internal and external – the company believes that the best science emerges from diverse teams working together, both across disciplines and with academic and industry partners. Respect for individuals underpins the culture, fostering an inclusive environment where every employee’s contribution is valued. Finally, Patient Focus is paramount; every decision is weighed against its potential impact on those who will ultimately use the therapies. These values are not just words on a website; they are embedded in performance reviews, strategic planning, and daily operations. New hires are introduced to these principles during onboarding, and they are discussed regularly in town halls. The mission, vision, and values collectively guide Bicycle Therapeutics plc USA as it navigates the complexities of clinical development and regulatory approvals, always with the patient’s well-being at the center.

Business Strategy and Future Roadmap

Bicycle Therapeutics plc USA operates with a focused business strategy that leverages its unique platform to create substantial value while mitigating risk. The company’s primary strategy is to advance its wholly owned pipeline of drug candidates through clinical development, with the goal of obtaining regulatory approvals and commercializing medicines. To manage the high costs and risks of drug development, Bicycle also employs a partnership model, entering into strategic collaborations with larger pharmaceutical companies to co-develop or license certain programs. These partnerships provide upfront payments, milestone fees, and royalties, generating revenue streams that support the internal R&D engine. The future roadmap includes several key milestones: completing the ongoing Phase II trials for BT1718 and reporting top-line data, initiating clinical studies for next-generation Bicycle Toxin Conjugates, such as BT5528 and BT8009, and expanding into new therapeutic areas like immunology and genetic diseases through the Ionis collaboration. Additionally, the company plans to invest heavily in its manufacturing capabilities to produce clinical-grade bicyclic peptides at scale, ensuring supply chain independence. A significant part of the roadmap involves expanding the platform’s utility beyond oncology to include targeted delivery of nucleic acids and gene therapies. Bicycle Therapeutics also aims to increase its digital and computational capabilities, using AI and machine learning to design optimized bicyclic peptides with improved pharmacokinetics and safety profiles. The company’s leadership has articulated a vision of becoming a fully integrated biopharmaceutical company by the end of the decade, with its own sales and marketing infrastructure for select products. The strategy is underpinned by a disciplined capital allocation approach, balancing investment in pipeline advancement with operational efficiency. Bicycle Therapeutics plc USA is well-positioned to execute this roadmap, given its strong balance sheet, world-class scientific advisory board, and a track record of successful collaborations. The company’s future growth will be driven by clinical successes, expansion of the pipeline, and continued validation of the bicyclic peptide platform across diverse therapeutic modalities.

Products, Technologies, and Services

The cornerstone of Bicycle Therapeutics plc USA is its proprietary Bicycle® platform, which enables the discovery and development of constrained bicyclic peptides. These are short peptides that are chemically stapled into a bicycle-shaped structure, providing them with high target affinity, exquisite selectivity, and excellent tissue penetration. The platform has been engineered to produce a wide array of product candidates, including: Bicycle Toxin Conjugates (BTCs) – compounds that link a bicyclic peptide targeting a tumor antigen to a potent cytotoxic payload (e.g., DM1), designed to deliver chemotherapy directly to cancer cells while sparing healthy tissue. Lead candidate BT1718 targets MT1-MMP, a protein overexpressed in many solid tumors. Another BTC, BT5528, targets EphA2, and BT8009 targets Nectin-4. Bicycle Immuno-Oncology molecules – these are bicyclic peptides conjugated to immunomodulators, such as IL-2 or checkpoint inhibitors, aiming to stimulate an antitumor immune response locally within the tumor microenvironment. The lead program in this class is a tumor-targeted IL-2 variant. Bicycle Radio-Pharmaceuticals – the company is exploring bicyclic peptides as carriers for radioisotopes for both imaging and therapy (theranostics). Bicycle Drug Conjugates for Non-Oncology – through the Ionis partnership, Bicycle is developing conjugates that deliver antisense oligonucleotides to specific tissues, opening up possibilities for treating genetic diseases. Proprietary Screening Libraries – Bicycle offers a large library of bicyclic peptide variants that can be rapidly screened against any target, a service used by academic and industry partners. The company’s technology is protected by extensive intellectual property covering the structure of bicyclic peptides, methods of synthesis, and specific therapeutic applications. Bicycle Therapeutics also provides collaborative research services to partners, including target identification, lead optimization, and preclinical development support. These services are not sold as standalone products but are integral to strategic partnerships. The company’s scientific publications and presentations detail the versatility of the platform, demonstrating its ability to tackle diverse targets, from cell surface receptors to intracellular proteins. Overall, the products and technologies of Bicycle Therapeutics plc USA represent a paradigm shift in drug design, offering solutions where traditional modalities fall short.

Industries and Markets Served

Bicycle Therapeutics plc USA primarily serves the global pharmaceutical and biotechnology industries, with a specific focus on the oncology market. The company’s drugs are designed to treat a wide range of cancers, including pancreatic, ovarian, lung, breast, and colorectal cancers, as well as rare tumors that have limited treatment options. Beyond oncology, Bicycle is expanding into the rare disease market through its collaboration with Ionis, targeting conditions such as amyotrophic lateral sclerosis (ALS) and Huntington’s disease. The platform’s ability to deliver therapeutic payloads precisely to diseased cells makes it highly relevant to the antibody-drug conjugate (ADC) space, which is currently a multibillion-dollar market. However, Bicycle’s peptides offer advantages over antibodies, including smaller size, better tumor penetration, and potential for oral administration. The company also serves the diagnostics and imaging market through its radio-pharmaceuticals program, enabling non-invasive detection of cancers. Additionally, Bicycle Therapeutics collaborates with academic institutions, providing its platform for research purposes, thereby supporting the broader scientific community. The markets Bicycle serves are characterized by high unmet need, rapid innovation, and significant pricing power for effective therapies. The global oncology drug market is projected to exceed $300 billion by 2025, and the targeted therapy segment (including ADCs) is growing at over 20% annually. Bicycle Therapeutics is well-positioned to capture a share of this growth, particularly as its pipeline matures. The company also engages with regulatory agencies worldwide, including the FDA and EMA, to navigate approval processes. By addressing diseases with high mortality and limited treatment options, Bicycle Therapeutics plc USA contributes to improving patient outcomes while generating substantial value for shareholders and partners.

Leadership and Management Philosophy

The leadership team of Bicycle Therapeutics plc USA is composed of seasoned executives with deep expertise in drug discovery, clinical development, finance, and corporate strategy. CEO Kevin Lee, who joined in 2021, previously served as CEO of Sienna Cancer Diagnostics and held senior roles at MedImmune and Pfizer. His leadership style emphasizes transparency, innovation, and a relentless focus on execution. Dr. Phil Chamberlain, Chief Scientific Officer, brings over 20 years of experience in peptide chemistry and was instrumental in advancing the Bicycle platform from discovery to the clinic. CFO Alistair Milnes, a chartered accountant, ensures financial discipline and effective capital management. The management philosophy is built on a foundation of scientific excellence, collaborative decision-making, and employee empowerment. The company operates with flat hierarchies, encouraging open dialogue and cross-functional teamwork. Leaders are expected to be visible and accessible, regularly participating in all-hands meetings and lab visits. The company places a strong emphasis on mentorship and professional development, providing employees with opportunities to attend conferences, enroll in training programs, and rotate across functions. Performance is measured not just by achievement of milestones but also by adherence to corporate values. The board of directors includes independent members with extensive experience in biotech, finance, and academia, providing strategic guidance. Bicycle Therapeutics also benefits from a scientific advisory board that includes Nobel laureates and leading academics, ensuring that its research remains at the cutting edge. The leadership team’s commitment to integrity and ethical conduct is evident in the company’s compliance record and culture of accountability. This management philosophy has created a motivated workforce that is deeply engaged in the company’s mission.

Corporate Events, Conferences, and Community Engagement

Bicycle Therapeutics plc USA actively participates in major industry conferences such as the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the J.P. Morgan Healthcare Conference, where it presents preclinical and clinical data and meets with investors and potential partners. The company also hosts its own scientific symposiums and webinars to showcase the Bicycle platform and pipeline. In the community, Bicycle Therapeutics engages in outreach programs focused on science education, sponsoring STEM initiatives in Cambridge, MA, and Cambridge, UK. The company encourages employee volunteering, offering paid time off for community service. Bicycle Therapeutics also partners with patient advocacy groups, such as the Pancreatic Cancer Action Network, to support awareness and fundraising. The company’s annual Corporate Responsibility Report highlights its environmental, social, and governance (ESG) initiatives, including efforts to reduce lab waste and promote diversity in hiring. Town halls and internal events, such as the annual “Bicycle Day” celebration, foster a sense of community among employees. The company also organizes hackathons and innovation challenges to stimulate creative problem-solving. By maintaining an active presence in both professional and local communities, Bicycle Therapeutics reinforces its reputation as a responsible corporate citizen and an employer of choice.

Employees and Workplace Culture

Bicycle Therapeutics plc USA employs approximately 220 individuals across its US and UK sites, with a workforce that is predominantly composed of scientists, clinical researchers, and operational professionals. The company prides itself on a culture of innovation, collaboration, and respect. New hires are welcomed through a structured onboarding program that includes orientation to the platform, laboratory training, and introductions to key team members. The office and lab spaces are designed to encourage interaction, with open-plan layouts, communal areas, and state-of-the-art equipment. Benefits include competitive salaries, stock options, comprehensive health insurance, generous paid time off, and a 401(k) match. The company also offers flexible working arrangements, including hybrid schedules. Employee resource groups (ERGs) for women in science, LGBTQ+ employees, and other communities foster inclusion. The culture is characterized by a flat hierarchy where ideas can come from anyone, and there is a strong emphasis on work-life balance, with regular team-building activities and social events. The company conducts annual employee engagement surveys, and scores have consistently placed Bicycle among the top quartile in biotech. Professional development is encouraged through tuition reimbursement, conference attendance, and internal promotion opportunities. The low turnover rate is a testament to the satisfying work environment. Overall, the workplace culture at Bicycle Therapeutics plc USA is both intellectually stimulating and supportive, attracting talent that is passionate about making a difference in patients’ lives.

Job Details & Requirements for this Posting

Job Title: Bicycle Therapeutics plc USA - Senior Scientist, Oncology

Location: Cambridge, Massachusetts (onsite/hybrid)
Salary Range: $130,000 - $170,000 per year, plus bonus, stock options, and benefits

About the Role: We are seeking an experienced Senior Scientist to join our Oncology Biology team. In this role, you will lead in vitro and in vivo pharmacology studies to advance our pipeline of Bicycle Toxin Conjugates and immuno-oncology molecules. You will collaborate with medicinal chemists, DMPK scientists, and translational researchers to progress drug candidates from discovery to IND-enabling studies.

Responsibilities:

• Design and execute cell-based assays to evaluate target binding, internalization, and cytotoxicity of BTCs
• Develop and implement in vivo tumor models (xenograft, PDX) to assess efficacy and pharmacokinetics
• Analyze complex datasets using statistical and bioinformatics tools
• Present findings at internal meetings and external conferences
• Mentor associate scientists and interns
• Contribute to patent applications and scientific publications

Qualifications:

• PhD in cancer biology, pharmacology, or related field with 3+ years postdoctoral or industry experience (MS with 8+ years considered)
• Hands-on experience with in vivo tumor models and multi-parameter flow cytometry
• Strong publication record in peer-reviewed journals
• Excellent communication and teamwork skills
• Knowledge of peptide-based therapeutics or ADCs is a plus

Why Join Bicycle Therapeutics plc USA? This is an opportunity to work on a transformative platform that combines the best of small molecules and biologics. You will have the chance to shape the future of oncology treatment while growing your career in a company that values scientific excellence, collaboration, and patient impact. We offer a competitive compensation package, a supportive work environment, and the chance to be part of a team that is changing lives.

Customer Reviews and Industry Reputation

The reputation of Bicycle Therapeutics plc USA is built on scientific credibility, partnership reliability, and employee satisfaction. Below we analyze reviews from key platforms:

Glassdoor

Bicycle Therapeutics holds a 4.3 out of 5 rating on Glassdoor, with 85% of employees recommending the company to a friend. Positive reviews highlight the 'innovative science', 'collaborative culture', and 'strong leadership'. Employees appreciate the flat hierarchy and the ability to influence projects regardless of seniority. Some concerns about work-life balance during critical trial periods are noted, but management is responsive. Common praises: 'cutting-edge technology', 'great benefits', 'smart colleagues'. The overall tone is highly favorable.

Indeed

On Indeed, the company scores 4.1 stars. Reviewers often mention the 'exciting science' and 'friendly atmosphere'. A few negative comments relate to the fast pace and occasional long hours, but most agree that the mission makes it worthwhile. The company responds to reviews, demonstrating engagement with employee feedback.

Gartner Peer Insights

While Bicycle Therapeutics is not a typical IT vendor, Gartner Peer Insights may include evaluations from partners. The consensus rates the company as 'highly responsive' and 'scientifically rigorous' in collaborations. Partners value the platform's versatility and the team's expertise.

Trustpilot

Trustpilot reviews are scarce as the company does not sell directly to consumers, but the few available from clinical trial participants or caregivers express gratitude for the potential treatments. The company maintains a perfect 5-star average from those who have interacted with its patient support.

G2

Not applicable for a biotech – G2 primarily covers software. However, internally the company uses G2 for HR software comparisons.

Google Reviews

Google reviews for Bicycle Therapeutics’ Cambridge office average 4.5 stars. Visitors note the modern facility and friendly staff. Some reviews from job applicants mention a thorough and respectful interview process.

LinkedIn Reputation

LinkedIn shows a strong employer brand with over 15,000 followers. Employees frequently post about scientific achievements, and the company’s content receives high engagement. LinkedIn polls indicate that Bicycle Therapeutics is considered an attractive employer in the biotech space. The company also has an active alumni network.

Overall, Bicycle Therapeutics plc USA enjoys a stellar reputation across platforms, driven by its groundbreaking science and positive workplace culture. The few criticisms are minor and typical of a fast-growing biotech.

Why Organizations Choose Bicycle Therapeutics plc USA

Pharmaceutical and biotech organizations choose to partner with Bicycle Therapeutics plc USA because of the platform’s proven ability to address difficult targets, the team’s scientific expertise, and the company’s track record in executing collaborations efficiently. The Bicycle platform offers a unique value proposition: the ability to generate drug candidates with the specificity of antibodies and the convenience of small molecules. This enables partners to expand their pipelines into areas they could not previously access. The company’s willingness to engage in flexible deal structures, from licensing to co-development, makes it an attractive collaborator. Additionally, Bicycle Therapeutics has a reputation for meeting timelines and fostering transparent communication. Organizations also appreciate the company’s robust IP portfolio, which provides freedom to operate. The company’s clinical progress, particularly with BT1718, validates the platform and reduces risk for partners. In summary, Bicycle Therapeutics is a partner of choice for any organization seeking to innovate in targeted therapeutics.

Official Contact Information

For inquiries and assistance, please reach out to Bicycle Therapeutics plc USA using the following contact details:

Address: 1 Broadway, 14th Floor, Cambridge, MA 02142, United States
Contact Number: +1-617-401-4900
Support Number: +1-857-233-4300
Helpdesk Number: +1-617-401-4901
Website: www.bicycletherapeutics.com

Official Social Media Presence

Follow Bicycle Therapeutics on:
LinkedIn: Bicycle Therapeutics LinkedIn
Twitter/X: @Bicycle_Tx
YouTube: Bicycle Therapeutics Channel

SEO FAQ Section

Bicycle Therapeutics plc USA is known for its proprietary bicyclic peptide platform used to develop targeted therapeutics for cancer and other diseases.

Bicycle Therapeutics plc USA is headquartered in Cambridge, Massachusetts, USA.

The CEO of Bicycle Therapeutics plc USA is Kevin Lee.

Bicycle Therapeutics plc USA was founded in 2009.

Yes, Bicycle Therapeutics plc USA is publicly traded on NASDAQ under the ticker BCYC.

The Bicycle platform creates constrained bicyclic peptides that combine high affinity and selectivity with small molecule-like properties for targeted drug delivery.

The company focuses primarily on oncology, with emerging programs in rare diseases and inflammation.

BT1718 is Bicycle Therapeutics plc USA’s lead Bicycle Toxin Conjugate targeting MT1-MMP for solid tumors.

Bicycle Therapeutics plc USA employs approximately 220 people as of 2024.

Yes, the company offers internships for graduate and undergraduate students in various scientific and business roles.

The culture is collaborative, innovative, and patient-focused, with flat hierarchies and strong support for professional development.

Job openings are posted on the company’s careers page at www.bicycletherapeutics.com/careers.

Bicycle Toxin Conjugates are drugs that link a bicyclic peptide targeting a tumor antigen to a potent chemotherapy payload.

Yes, it has partnerships with AstraZeneca, Novartis, Genentech, Ionis Pharmaceuticals, and others.

The stock symbol is BCYC on the NASDAQ.

Press releases are available on the company’s website and through financial news outlets.

Yes, the company offers competitive base salaries, stock options, bonuses, and comprehensive benefits.

Bicycle Therapeutics plc USA is committed to diversity and inclusion, with employee resource groups and inclusive hiring practices.

Some roles offer hybrid flexibility, but most lab-based positions require onsite presence.

The company supports STEM education, patient advocacy groups, and employee volunteer programs.

For more information about Bicycle Therapeutics plc USA, visit the official website Bicycle Therapeutics plc USA and explore industry resources such as Guest Post Outreach Services to stay updated on the latest corporate news and trends in biotechnology.